

REMARKS


Claims 1-9 have been cancelled as being in a "use" format not generally acceptable under United States Practice. Independent claims 12 and 13 have been amended to insert "in need thereof" to define the patient to whom the method is applied, and to delete "such as a human" as not being in accordance with United States practice. Minor formal amendments have been made to dependent claims 14, 15 and 16 and their dependencies have been updated to include new claims 17 and 18. New method claims 17 and 18 have been added, which are patterned after the methods of claims 12 and 13, except are directed toward the treatment of a cancer involving a solid tumour. Support for the treatment of a cancer involving a solid tumour is found, *inter alia*, at page 8, lines 21-25 of the specification as filed. No new matter is added by these amendments, and entry thereof is believed to be in order and is respectfully requested. Following entry of these amendments, claims 10-18 are pending in this application.

No additional fees are believed due other than those charged with this new application filing. However, any and all charges or credits should be submitted to the Morgan Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: September 25, 2006
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:



Donald I. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001